Business News

Servier Acquires Non-Hodgkin B-Cell Lymphoma Treatment Pixuvri from CTI BioPharma

PARIS–(BUSINESS WIRE)–Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI …

Read More »

NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Company Focused on Developing Rare Disease Drugs

AUSTIN, Texas and AMES, Iowa, Sept. 30, 2019 (GLOBE NEWSWIRE) — NewLink Genetics Corporation (NASDAQ:NLNK) and Lumos Pharma, Inc., a private clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare diseases, today announced that the companies have entered into a definitive merger agreement. Under the terms …

Read More »

Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and the Broad Institute of MIT and Harvard today announced they have entered into a collaboration for the co-development of secondary genomic analysis algorithms and software. Top data scientists from both institutions will collaborate to bring together the industry-leading open-source GATK algorithms with the speed and …

Read More »

Vertex and Ribometrix Enter Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

BOSTON & DURHAM, N.C.–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and RNA therapeutics developer Ribometrix, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small …

Read More »

Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Hematology

STOCKHOLM, Sept. 30, 2019 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 per share in cash and, one non-tradeable Contingent Value …

Read More »

Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a multi-year research collaboration with Harvard University with the goal of identifying and developing novel therapeutic approaches that could improve the …

Read More »

Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

CAMBRIDGE, Mass. and SAN CARLOS, Calif., Sept. 25, 2019 /PRNewswire/ — Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical customers who order FoundationOne®CDx. The initial focus of the partnership …

Read More »

Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx

SEATTLE, Wash., Sept. 24, 2019 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with Illumina, Inc. (Nasdaq: ILMN) to develop in-vitro diagnostic …

Read More »

Clovis Oncology Acquires Rights to 3B Pharmaceuticals’ FAP-Targeted Radiopharmaceutical Program

BOULDER, Colo. & BERLIN–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. The initial focus is on developing a …

Read More »

I-Mab Biopharma Enters Clinical Collaboration to Evaluate TJC4 with Keytruda for Treatment of Multiple Cancer Types

SHANGHAI, Sept. 23, 2019 /PRNewswire/ — I-Mab Biopharma (“I-Mab”), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, today announced that it has entered into a clinical research collaboration agreement with MSD, a …

Read More »